These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2580291)

  • 1. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
    Kates RE; Jaillon P; Rubenson DS; Winkle RA
    Clin Pharmacol Ther; 1980 Jul; 28(1):52-7. PubMed ID: 6156049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylprocainamide kinetics and clinical response during repeated dosing.
    Rodman JH; Hurst A; Gaarder T; Cohen J; Jelliffe RW
    Clin Pharmacol Ther; 1982 Sep; 32(3):378-86. PubMed ID: 6179685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Acetylprocainamide kinetics after single and repeated oral doses.
    Ludden TM; Crawford MH
    Clin Pharmacol Ther; 1982 Mar; 31(3):343-9. PubMed ID: 6174262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
    Winkle RA; Jaillon P; Kates RE; Peters F
    Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related pharmacokinetics of N-acetylprocainamide in rats.
    Yacobi A; Kamath BL; Stampfli HF; Look ZM; Lai CM
    J Pharm Sci; 1983 Jul; 72(7):789-92. PubMed ID: 6193264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of procainamide hydrochloride in dogs.
    Papich MG; Davis LE; Davis CA; McKiernan BC; Brown SA
    Am J Vet Res; 1986 Nov; 47(11):2351-8. PubMed ID: 2431636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procainamide elimination kinetics in pediatric patients.
    Singh S; Gelband H; Mehta AV; Kessler K; Casta A; Pickoff AS
    Clin Pharmacol Ther; 1982 Nov; 32(5):607-11. PubMed ID: 7128001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.
    Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM
    Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of N-acetylprocainamide in heart disease.
    Crawford MH; Ludden TM; Kennedy GT; Sodums MT; O'Rourke RA; Amon KW
    Clin Pharmacol Ther; 1982 Apr; 31(4):459-65. PubMed ID: 6174263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.